Is there an effect of intranasal insulin on development and behaviour in Phelan-McDermid syndrome? A randomized, double-blind, placebo-controlled trial

European Journal of Human Genetics

Volumn 24, Issue 12, 2016, Pages 1696-1701

  Zwanenburg, Renée J ^a   Bocca, Gianni ^b   Ruiter, Selma A J ^c   Dillingh, Jan H ^d   Flapper, Boudien C T ^b   Van Den Heuvel, Edwin R ^e   Van Ravenswaaij Arts, Conny M A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c Centre of Expertise for Child Development Care and Research   (Netherlands)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

^e EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; GLUCOSE; PLACEBO; RECOMBINANT HUMAN INSULIN; INSULIN; NERVE PROTEIN; SHANK3 PROTEIN, HUMAN;

ABDOMINAL PAIN; ADAPTIVE BEHAVIOR; ADOLESCENT; ADULT; ARTICLE; CHILD; CHILD BEHAVIOR; CHILD DEVELOPMENT; CHROMOSOME 22Q; CHROMOSOME DELETION; CLINICAL ARTICLE; COGNITIVE DEVELOPMENT; COMMUNICATION SKILL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; EMOTION; EPISTAXIS; FEMALE; GASTROENTERITIS; GENE; HUMAN; LANGUAGE DEVELOPMENT; MALE; MEDICATION COMPLIANCE; MOTOR DEVELOPMENT; MOTOR PERFORMANCE; NOSE IRRITATION; OUTCOME ASSESSMENT; PANCREATITIS; PATIENT COMPLIANCE; PHELAN-MCDERMID SYNDROME; PILOT STUDY; PRIORITY JOURNAL; PROBLEM BEHAVIOR; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHANK3 GENE; SIDE EFFECT; SOCIAL ADAPTATION; SOCIAL BEHAVIOR; SOCIAL EVOLUTION; UPPER RESPIRATORY TRACT INFECTION; CHROMOSOME 22; CHROMOSOME DISORDERS; GENETICS; INFANT; INTRANASAL DRUG ADMINISTRATION; PRESCHOOL CHILD; SOCIAL COMPETENCE;

ADMINISTRATION, INTRANASAL; ADOLESCENT; CHILD; CHILD DEVELOPMENT; CHILD, PRESCHOOL; CHROMOSOME DELETION; CHROMOSOME DISORDERS; CHROMOSOMES, HUMAN, PAIR 22; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFANT; INSULIN; MALE; NERVE TISSUE PROTEINS; SOCIAL SKILLS;

EID: 84984846872     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2016.109     Document Type: Article

References (35)

1. Phelan K, McDermid HE: The 22q13.3 deletion syndrome (phelan-mcdermid syndrome). Mol Syndromol 2012; 2: 186-201.
2. Oberman LM, Boccuto L, Cascio L, Sarasua S, Kaufmann WE: Autism spectrum disorder in Phelan-McDermid syndrome: initial characterization and genotypephenotype correlations. Orphanet J Rare Dis 2015; 10: 105.
3. Zwanenburg RJ, Ruiter SAJ, Van den Heuvel ER, Flapper BCT, Van Ravenswaaij-Arts CMA: Developmental phenotype in Phelan-McDermid (22q13.3 deletion) syndrome: a systematic and prospective study in 34 children. J Neurodev Disord 2016; 8: 16.
4. Wilson HL, Wong ACC, Shaw SR et al: Molecular characterisation of the 22q13 deletion syndrome supports the role of haploinsufficiency of SHANK3/PROSAP2 in the major neurological symptoms. J Med Genet 2003; 40: 575-584.
5. Leblond CS, Nava C, Polge A et al: Meta-analysis of SHANK mutations in autism spectrum disorders: a gradient of severity in cognitive impairments. PLoS Genet 2014; 10: e1004580.
6. Bozdagi O, Sakurai T, Papapetrou D et al: Haploinsufficiency of the autism-associated Shank3 gene leads to deficits in synaptic function, social interaction, and social communication. Mol Autism 2010; 1: 15.
7. Yang M, Bozdagi O, Scattoni ML et al: Reduced excitatory neurotransmission and mild autism-relevant phenotypes in adolescent Shank3 null mutant mice. J Neurosci 2012; 32: 6525-6541.
8. Halbedl S, Schoen M, Feiler MS, Boeckers TM, Schmeisser MJ: Shank3 is localized in axons and presynaptic specializations of developing hippocampal neurons and involved in the modulation of NMDA receptor levels at axon terminals. J Neurochem 2016; 137: 26-32.
9. Shcheglovitov A, Shcheglovitova O, Yazawa M et al: SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients. Nature 2013; 503: 267-271.
10. Bozdagi O, Tavassoli T, Buxbaum JD: Insulin-like growth factor-1 rescues synaptic and motor deficits in a mouse model of autism and developmental delay. Mol Autism 2013; 4: 9.
11. Kolevzon A, Bush L, Wang AT et al: A pilot controlled trial of insulin-like growth factor-1 in children with Phelan-McDermid syndrome. Mol Autism 2014; 5: 54.
12. Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL: Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 2002; 5: 514-516.
13. Shemesh E, Rudich A, Harman-Boehm I, Cukierman-Yaffe T: Effect of intranasal insulin on cognitive function: a systematic review. J Clin Endocrinol Metab 2012; 97: 366-376.
14. Craft S, Baker LD, Montine TJ et al: Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012; 69: 29-38.
15. Schmidt H, Kern W, Giese R, Hallschmid M, Enders A: Intranasal insulin to improve developmental delay in children with 22q13 deletion syndrome: an exploratory clinical trial. J Med Genet 2009; 46: 217-222.
16. Van den Heuvel ER, Zwanenburg RJ, Van Ravenswaaij-Arts CM: A stepped wedge design for testing an effect of intranasal insulin on cognitive development of children with Phelan-McDermid syndrome: a comparison of different designs. Stat Methods Med Res; e-pub ahead of print 19 November 2014; pii: 0962280214558864.
17. Benedict C, Hallschmid M, Schmitz K et al: Intranasal insulin improves memory in humans: superiority of insulin aspart. Neuropsychopharmacology 2007; 32: 239-243.
18. Näntö-Salonen K, Kupila A, Simell S et al: Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 2008; 372: 1746-1755.
19. Bartholomeusz HH, Courchesne E, Karns CM: Relationship between head circumference and brain volume in healthy normal toddlers, children, and adults. Neuropediatrics 2002; 33: 239-241.
20. Rushton JP, Ankney CD: Size matters: a review and new analyses of racial differences in cranial capacity and intelligence that refute Kamin and Omari. Personal Individ Differ 2000; 29: 591-620.
21. Fredriks AM, van Buuren S, Burgmeijer RJ et al: Continuing positive secular growth change in The Netherlands 1955-1997. Pediatr Res 2000; 47: 316-323.
22. Bayley N: Bayley Scales of Infant and Toddler Development. Hartcourt Assessment: San Antonio, TX, USA, 2006.
23. Van Baar AL, Steenis LJP, Verhoeven M, Hessen DJ, Bayley III NL: Technische handleiding. Pearson Assessment and Information B.V.: Amsterdam, 2014.
24. Wechsler D: The Wechsler Preschool and Primary Scale of Intelligence. Pearson Assessment and Information: Amsterdam, 2009.
25. Hendriksen J, Hurks P, WPPSI-III NL: Wechsler Preschool and Primary Scale of Intelligence-Third Edition. Pearson Assessment and Information B.V.: Amsterdam, 2009.
26. Sparrow SS, Carter AS, Cicchetti DV: Vineland Screener: Overview, Reliability, Validity, Administration and Scoring. Yale University Child Study Center: New Haven, CT, USA, 1993.
27. Scholte EM, Van Duijn G, Dijkxhoorn YM, Noens ILJ, Van Berckelaer-Onnes IA: De Vineland screener 0-6. Pits: Leiden, Netherlands, 2008.
28. Hoekman J, Miedema A, Otten B, Gielen J: Experimentele Schaal voor de beoordeling van het Sociaal-Emotionele Ontwikkelingsniveau. Pits: Leiden, Netherlands, 2007.
29. Gioia GA, Espy KA, Isquith PK: Behavior Rating Inventory of Executive Function. Psychological Assessment Resources: Odessa, FL, USA, 2002.
30. ASEBA Achenbach System of Eperically Based Assessment www.aseba.nl.
31. Fernandez AM, Torres-Alemán I: The many faces of insulin-like peptidesignalling in the brain. Nat Rev Neurosci 2012; 13: 225-239.
32. Lee C-C, Huang C-C, Hsu K-S: Insulin promotes dendritic spine and synapse formation by the PI3K/Akt/mTOR and Rac1 signaling pathways. Neuropharmacology 2011; 61: 867-879.
33. Verpelli C, Dvoretskova E, Vicidomini C et al: Importance of Shank3 protein in regulating metabotropic glutamate receptor 5 (mGluR5) expression and signaling at synapses. J Biol Chem 2011; 286: 34839-34850.
34. Lee C-C, Huang C-C, Wu M-Y, Hsu K-S: Insulin stimulates postsynaptic density-95 protein translation via the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway. J Biol Chem 2005; 280: 18543-18550.
35. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH: Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004; 127: 481-496.